A Phase 2 interventional study of UBT251 and UBT251 Placebo in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Recruiting at 70 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S — 25 open to participants now, 29 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Novo Nordisk A/S.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 170th largest by planned enrollment of the 428 interventional ones that give a count, is one of 23 that started in 2026, is one of 37 in phase 2, reaches primary completion later than 9 of the 28 other live ones, and was the 633rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →25 of the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Germany
Ages 25–69 · Healthy volunteers
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Brazil and 13 more countries
Ages 45+
By country, each count listing its studies:
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
643 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 23 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 209 across the 428 interventional studies, 938 across the 215 observational. Of the 603 that completed or were terminated, 174 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
8 of the studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT05689372Novo Nordisk A/SRegulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | 2026-11-30 |
| NCT07532863Novo Nordisk A/SA Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants | 2027-03-27 |
Add all 8 to your calendar (.ics) → With an account.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
metformin with or without sodium-glucose cotransporter-2 (SGLT2) inhibitor.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once weekly UBT251 subcutaneously.
Drug: UBT251
Participants will receive once weekly UBT251 placebo subcutaneously.
Drug: UBT251 Placebo
Participants will receive once weekly semaglutide subcutaneously.
Drug: Semaglutide
Participants will receive once weekly semaglutide placebo subcutaneously.
Drug: Semaglutide Placebo
UBT251 will be administered subcutaneously once-weekly.
UBT251 placebo will be administered subcutaneously once-weekly.
Semaglutide will be administered subcutaneously once-weekly.
Semaglutide placebo will be administered subcutaneously once-weekly.
UBT251: Change in glycated haemoglobin (HbA1c)
Measured as percentage (%)-point.
Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)
UBT251: Relative change in body weight
Measured as %.
Time frame: From baseline (week 0) to week 40
UBT251: Change in body weight
Measured as kilogram (kg).
Time frame: From baseline (week 0) to week 40
UBT251 vs placebo: Change in HbA1c
Measured as %-point.
Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)
Change in HbA1c
Measured as %-point.
Time frame: From baseline (week 0) to week 40
Change in homeostasis model assessment of insulin resistance (HOMA2-IR)
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 40
Change in homeostasis model assessment of beta-cell function (HOMA2-B)
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 40
Change in fasting plasma glucose (FPG)
Measured as millimoles per litre (mmol/L).
Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)
CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 milligrams per deciliter (mg/dL))
Measured as %-points.
Time frame: From baseline (week -2 to week 0) to week 14- 16, week 26-28 and week 38-40, respectively
UBT251 vs placebo: Relative change in body weight
Measured as %.
Time frame: From baseline (week 0) to week 40
UBT251 vs placebo: Change in body weight
Measured as kg.
Time frame: From baseline (week 0) to week 40
Change in body mass index (BMI)
Measured as Kilograms per square meter (kg/m\^2).
Time frame: From baseline (week 0) to week 40
Change in waist circumference
Measured as centimeter (cm).
Time frame: From baseline (week 0) to week 40
Change in waist-to-height ratio (WHtR)
Time frame: From baseline (week 0) to week 40
Change in systolic blood pressure (SBP)
Measured as millimetres of mercury (mmHg).
Time frame: From baseline (week 0) to week 40
Change in diastolic blood pressure (DBP)
Measured as mmHg.
Time frame: From baseline (week 0) to week 40
Change in pulse rate
Measured in beats/min.
Time frame: From baseline (week 0) to week 40
Change in high sensitivity C-Reactive Protein (hsCRP)
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 40
Change in total cholesterol
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 40
Change in high-density lipoprotein (HDL) cholesterol
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 40
Change in low-density lipoprotein (LDL) cholesterol
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 40
Change in triglycerides
Measured as ratio to baseline.
Time frame: From baseline (week 0) to week 40
Change in urine albumin creatinine ratio (UACR)
Measured as ratio to baseline.
Time frame: From baseline (week 0) to 12 weeks on a given maintenance dose (week 16, 28 and 40)
Change in eGFR (creatinine-cystatin C-based CKD-EPI 2021)
Measured in milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2).
Time frame: From baseline (week 0) to week 40
Number of treatment-emergent adverse events (TEAEs)
Measured as number of events.
Time frame: From baseline (week 0) to week 46
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Oct 2027, 15 months after the start.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 15 months is above that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: UBT251